Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, has initiated a technology evaluation agreement in the area of in vivo CAR-T cell therapy with Acuitas Therapeutics, based in Canada. Current mRNA-based approaches are promising, but the short duration of expression of only a few days may limit their efficacy and applicability. Circio claims its proprietary circVec technology can achieve up to six months expression in lym...